Description: Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
Home Page: www.zailaboratory.com
Jinchuang Plaza
Shanghai,
201210
China
Phone:
86 21 6163 2588
Officers
Name | Title |
---|---|
Dr. Ying Du Ph.D. | Founder, Chairperson & CEO |
Mr. Ki Chul Cho | Chief Financial Officer |
Mr. Frazor Titus Edmondson III | Chief Legal Officer & Corp. Sec. |
Dr. Harald Reinhart M.D. | Pres and Head of Global Devel. for Neuroscience, Autoimmune & Infectious Diseases |
Mr. Joshua L. Smiley | Chief Operating Officer |
Dr. Peter Huang Ph.D. | Chief Scientific Officer |
Ms. Ann E. Beasley J.D. | Chief Compliance Officer |
Dr. Ning Xu M.D. | Exec. VP & Head of Clinical Operations |
Dr. Jonathan J. Wang M.B.A., MBA, Ph.D. | Chief Bus. Officer |
Dr. James Yan DABT, M.D., Ph.D. | Chief Operating Officer of R&D |
Exchange: HK
Country: HK
Currency: Hong Kong Dollar (HK$)
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 3.2213 |
Price-to-Sales TTM: | 129.7249 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 1951 |